Chargement en cours...

Developmental Therapeutics in Myeloproliferative Neoplasms

The unprecedented success of the Janus kinase (JAK) 1/2 inhibitor ruxolitinib in myelofibrosis provided much-needed impetus for clinical drug development for the Philadelphia chromosome negative myeloproliferative neoplasms (MPN). The survival benefit conferred by this agent, along with its marked e...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Lymphoma Myeloma Leuk
Auteurs principaux: Bose, Prithviraj, Verstovsek, Srdan
Format: Artigo
Langue:Inglês
Publié: 2017
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5540010/
https://ncbi.nlm.nih.gov/pubmed/28760302
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2017.02.014
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!